CIPLA.BO Cipla Limited
Company Analysis
Latest News
Cipla's Pune License Loss Adds to Regulatory Woes — How Deep Is the Damage to India's Third-Largest Drugmaker?
Reports emerged that Maharashtra's Food and Drug Administration cancelled the drug sale and distribution license for Cipla Pharma & Life Sciences' Pune...
Cipla loses Pune license, cited for misbranding and storage failures
The Maharashtra Food and Drug Administration (FDA) cancelled the drug sale and distribution license for Cipla Pharma & Life Sciences’ Pune facility. This...
Cipla Shares Rise, Securing US FDA Approval for Generic Advair Diskus
Cipla Limited received final U.S. FDA approval for its generic version of Advair Diskus. The approval covers all three strengths of the fluticasone propionate...
Cipla Profit Plunges 39% on Weak US Sales, Appoints New CFO
Cipla reported a 39% year-over-year decline in first-quarter consolidated net profit to ₹789 crore. The result missed analyst expectations and marks the...
Cipla Shares Sink, Trump Proposes 200% Tariffs on Generic Drug Imports
Cipla and major Indian pharmaceutical shares fell up to 2.5% on July 22, 2026. US President Donald Trump announced plans for 100-200% tariffs on imported...